RBC Capital analyst Kennen MacKay lowered his price target on Puma Biotechnology to $26 and kept his Sector Perform rating after attending the presentation on the updated KATHERINE data in high-risk adjuvant human epidermal growth factor receptor 2, or HER2, / breast cancer at the San Antonio Breast Cancer Symposium. The analyst cites increased competition for Puma's Nerlynx coming from Genentech's Kadcyla's entry into the breast cancer market with indicated benefits for high risk patients and "strong benefit in HER2+/HR+ patients" where Nerlynx was expected to generate most of its sales.